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Abstract
Aboriginal and Torres Strait Islander people have a substantially higher prevalence of liver disease than
non-Indigenous Australians. Cirrhosis and its complications were the sixth leading cause of mortality for
Aboriginal and Torres Strait Islander people in 2020. Liver disease has been estimated to be the third
leading cause of the mortality gap between Aboriginal and Torres Strait Islander and non-Indigenous
people due to chronic disease, accounting for 11% of this gap. While current trends show reducing
mortality rates for Aboriginal and Torres Strait Islander people for conditions including circulatory
disease, diabetes and kidney disease, there are no data to suggest a similar decline for liver disease. This
review highlights the common causes of liver disease affecting Aboriginal and Torres Strait Islander
people, which include hepatitis B, hepatitis C, alcohol related liver disease, metabolic dysfunctionassociated fatty liver disease, and cirrhosis and its complications including hepatocellular carcinoma.
Current treatments including liver transplantation as well as suggestions for improving detection,
treatment and access to liver care will also be discussed. Recent revolutions in the detection and
treatment of liver disease make efforts to improve access to treatment and outcomes an urgent priority
for Aboriginal and Torres Strait Islander people.
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Aboriginal and Torres Strait Islander people are disproportionately affected by liver
disease. Cirrhosis and its complications such as liver cancer was the sixth leading cause of
mortality for Aboriginal and Torres Strait Islander people in 2020 (Australian Bureau of
Statistics [ABS], 2021). Only ischaemic heart disease, diabetes, chronic lower respiratory
diseases, respiratory malignancy and suicide accounted for a greater number of deaths. In
addition, mortality rates from cirrhosis and liver disease were 3.2-fold higher in Aboriginal
and Torres Strait Islander people compared to non-Indigenous people, the highest rate ratio
for any disease other than diabetes and chronic lower respiratory diseases (4.9 and 3.4,
respectively). Moreover, liver disease has been estimated to be the third leading cause of
the mortality gap between Aboriginal and Torres Strait Islander and non-Indigenous people
due to chronic disease, accounting for 11% of this mortality gap, following ischaemic heart
disease (22%) and diabetes (12%) (Australian Institute of Health and Welfare [AIHW], 2010).
While current trends show reducing mortality rates for Aboriginal and Torres Strait Islander
people for many important diseases including circulatory disease, diabetes and kidney
disease, there are no data to suggest a similar decline for liver disease. Indeed, the current
obesity epidemic is likely to be a major driver into the future of liver disease morbidity and
mortality.
Despite the significant morbidity and mortality from liver disease among Aboriginal
and Torres Strait Islander people, the problem has received a low priority from a health
education, planning and research perspective. This review will therefore discuss the
common causes of liver disease affecting Aboriginal and Torres Strait Islander people which
include hepatitis B, hepatitis C, alcohol related liver disease, and metabolic dysfunctionassociated fatty liver disease and their current treatments including liver transplantation. It
will also discuss cirrhosis and its complications including hepatocellular carcinoma (HCC).
Suggestions for how to improve the detection and treatment and access to liver care will also
be discussed.

Published by Edith Cowan University, 2022

1

Journal of the Australian Indigenous HealthInfoNet, Vol. 3 [2022], Iss. 4, Art. 5

Hepatitis B
Historically, Aboriginal and Torres Strait Islander people have played a vital part in
the discovery of hepatitis B (HBV) with the hepatitis B surface antigen first discovered from
the serum of Aboriginal and Torres Strait Islander people (Blumberg & Alter, 1965). Hepatitis
B is an ancient infection which has likely existed among this population for thousands of
years (Davies et al., 2013). The overall HBV prevalence in the Aboriginal and Torres Strait
Islander population is more than two-fold that of the non-Indigenous population (2.5% versus
0.95%) with an even higher estimated prevalence of 5.5% in remote/very remotely living
Aboriginal and Torres Strait Islander people (AIHW, 2017). Aboriginal and Torres Strait
Islander people have evolved a unique HBV genotype (genotype C4) (Littlejohn et al., 2014)
which appears to be associated with a greater risk of chronic liver disease, hepatocellular
carcinoma and potential for vaccine failure.
Hepatitis B vaccination is a cornerstone for the prevention of the virus, resulting in
reduced rates of infection and its associated complications in vaccinated populations
(Chang, 2011). The universal HBV vaccination program was introduced in the year 2000 for
infants in Australia and current recommendations are for HBV screening for all Aboriginal
and Torres Strait Islander people and vaccination of all Aboriginal and Torres Strait Islander
people who are non-immune (National Aboriginal Community Controlled Health Organisation
& The Royal Australian College of General Practitioners, 2018). Nationally, full immunisation
of infants by 12 months of age has reached the 95% target (MacLachlan et al., 2019), yet
vaccination rates in Aboriginal and Torres Strait Islander children younger than 12 months of
age is lower at 93% (Kirby Institute, 2018). However, by 24 months of age, the vaccination
rate among Aboriginal and Torres Strait Islander children was found to be higher at 98%
compared to 96% among non-Indigenous children between 2013-2017. Nevertheless, the
rate of new infections remains higher in Aboriginal and Torres Strait Islander people
compared to non-Indigenous people with the notification rate 2.3 times that of nonIndigenous people in 2017 (45.1 per 100 000 vs 19.2 per 100 000) (Kirby Institute, 2018).
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Furthermore, this does not factor in under-reporting of cases with only approximately 50% of
notifications including Aboriginal and Torres Strait Islander status at the time.
The difficulties of delivering HBV care in remote Aboriginal and Torres Strait Islander
communities has been highlighted in a recent study of patients attending a remote Aboriginal
and Torres Strait Islander health service (Narayana et al., 2021). The study found high rates
of both chronic HBV infection (12%) and resolved infection (20%). Only 52% of patients had
been screened for HBV infection and 48% had completed a full HBV vaccination course.
A further concern is possible suboptimal response to the vaccine in Aboriginal and
Torres Strait Islander people, with high rates of breakthrough HBV infection noted (Dent et
al. 2010; Hanna et al., 1997). In the study by Narayana et al. (2021), 24% of patients had
sub-therapeutic levels of hepatitis B surface antibody (HBsAb) (<10 IU/mL) and 6% had
breakthrough HBV infection despite being fully vaccinated. It has been suggested that
primary vaccine failure may be the reason behind the subtherapeutic HBsAb levels with 22%
of participants in the study failing to seroconvert despite prospective vaccination. These
findings are consistent with previous reports (Dent et al., 2010; Griffiths et al., Hanna et al.,
1997; 2014). The reasons for possible lower seroconversion and protection following HBV
vaccination in Aboriginal and Torres Strait Islander people are unknown.
Immunosuppression related to a higher comorbidity burden seen in Aboriginal and Torres
Strait Islander people as well as a mismatch between the serotype used in the HBV vaccine
(A2 subgenotype) and the main serotype affecting Aboriginal and Torres Strait Islander
people (C4 subgenotype) are potential causes contributing to vaccine failure (Cheah et al.,
2018; Davies et al., 2013; Littlejohn et al., 2014). Overall, further research into HBV in
Aboriginal and Torres Strait Islander people is needed, including exploring the need for an
alternative to the current vaccine available.
Once HBV infection has been detected, long-term six-monthly monitoring of chronic
infection is vital. Chronic infection (characterised by positive hepatitis B surface antigen) can
transition from inactive infection to active hepatitis and requires regular monitoring with sixmonthly liver function tests and viral load. Active hepatitis is asymptomatic and without
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treatment can lead to liver fibrosis, cirrhosis, liver failure and HCC. For patients with active
hepatitis, highly effective antiviral agents (entecavir, tenofovir) are available, and treatment
can substantially reduce complications including cirrhosis and HCC. Aboriginal and Torres
Strait Islander people with chronic HBV infection who are over 50 years old, have an
increased risk of HCC and should be offered six-monthly liver ultrasound surveillance.
Ultrasound surveillance in HBV has been shown to reduce mortality in the surveillance group
due to early detection of smaller, curable tumours (Zhang et al., 2004).
Improving engagement in HBV care via increased uptake of monitoring and
treatment should be a major goal in Aboriginal and Torres Strait Islander health. Promising
models have been described in remote settings involving co-designed, culturally appropriate
mobile liver clinics (Hla et al., 2020) aimed at improving uptake of monitoring, treatment and
HCC surveillance.
Hepatitis C
Hepatitis C (HCV) is another blood-borne virus that disproportionally affects
Aboriginal and Torres Strait Islander people, with a prevalence of 4.4% and 0.94% between
Aboriginal and Torres Strait Islander and non-Indigenous populations, respectively (Hepatitis
C Estimates and Projections Working Group, 2006). While Aboriginal and Torres Strait
Islander people comprise 2.8% of the population, they account for 9% of the patients
diagnosed with HCV (Kirby Institute, 2016). Between 2013 to 2017, notification of hepatitis C
infection in Aboriginal and Torres Strait Islander people increased by approximately 15%,
whereas it decreased in non-Indigenous people by 12%. In Aboriginal and Torres Strait
Islander males, the rate of infection increased by 28.5% whilst in Aboriginal and Torres Strait
Islander females, the rate decreased by 6%. The higher prevalence of HCV in Aboriginal and
Torres Strait Islander people can be attributed in part to their over representation in high-risk
groups such as people in custody and people who use intravenous drugs (Brener et al.,
2016).
Screening and detection of HCV has become increasingly important following the
recent revolution in HCV therapy and the availability of direct acting antivirals (DAAs)
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(Pawlotsky et al., 2015). Unlike prior ineffective and highly toxic interferon-based therapies,
DAA medications can ‘cure’ HCV infection in 95% of individuals without a significant side
effect profile. Commonly prescribed regimens include Sofosbuvir/Velpatasvir (Epclusa®, one
tablet taken daily for 12 weeks) and Glecaprevir/Pibrentasvir (Maviret®, three tablets daily
for eight weeks) and are now commonly prescribed in primary care (Hepatitis C Virus
Infection Consensus Statement Working Group, 2020).
However, uptake of these medications by Aboriginal and Torres Strait Islander
people remains low compared to the general population. In the 2016 Australian Needle and
Syringe Program Survey, 18% of Aboriginal and Torres Strait Islander respondents who
have HCV and inject drugs had been treated for HCV over the past year in contrast to 23%
of non-Indigenous respondents (Kirby Institute, 2017). Aboriginal and Torres Strait Islander
participants in the REACH-C study of HCV treatment had a higher rate of loss to follow up
(24% compared to 15% for non-Indigenous people) (Yee et al., 2022). However, overall,
Aboriginal and Torres Strait Islander status was not associated with loss to follow-up
following adjusted analysis (OR=1.21 [1.00-1.46] p=0.05). Increasing HCV screening and
treatment uptake for Aboriginal and Torres Strait Islander people should now be an
important priority. Part of this challenge involves reducing barriers to treatment including the
stigma and shame associated with HCV which prevents Aboriginal and Torres Strait Islander
people openly discussing HCV with healthcare providers, family and friends as well as the
wider community (Brener et al., 2016). Programs such as dedicated liver clinics which
include support from Aboriginal and Torres Strait Islander Health Workers, specialist nurses,
general practitioners and oversight from physicians have been effective in improving access
to HCV treatment in Aboriginal and Torres Strait Islander communities (Wallace et al., 2018).
However, more programs are needed to improve access to HCV treatment among Aboriginal
and Torres Strait Islander people in order to prevent progression towards cirrhosis and its
complications and to reduce ongoing HCV transmission by infected individuals.
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Alcohol Related Liver Disease
Similar to other diseases affecting the liver, Aboriginal and Torres Strait Islander
people are affected by alcohol-related liver disease more than non-Indigenous people.
Aboriginal and Torres Strait Islander people are 1.2 times more likely to ingest alcohol at
harmful levels compared to non-Indigenous people, according to recent data (Gray et al.,
2018). The issue affects Aboriginal and Torres Strait Islander males more than females, with
males more than twice as likely to consume harmful amounts of alcohol. During the period
2014 to 2018, mortality from alcohol related causes was higher among Aboriginal and Torres
Strait Islander people, with 31 per 100,000 Aboriginal and Torres Strait Islander males dying
from alcohol related causes compared to 7.2 per 100,000 non-Indigenous males (AIHW,
2020). Amongst females, 11 per 100,000 Aboriginal and Torres Strait Islander females died
from alcohol related causes compared to 2.3 per 100,000 non-Indigenous females (AIHW,
2020). Alcohol related liver disease was the most common cause of alcohol related deaths
and accounts for the majority of liver disease related mortality in Aboriginal and Torres Strait
Islander people.
Harmful alcohol use among Aboriginal and Torres Strait Islander people is a complex
issue which relates to broader social factors and historical events including colonisation,
segregation and dispossession of culture and land (Gray et al., 2018). Recent data
demonstrate a number of encouraging trends concerning alcohol use in Aboriginal and
Torres Strait Islander people, including a 1.3-fold higher rate of alcohol abstinence in
Aboriginal and Torres Strait Islander versus non-Indigenous people. Of note, in 2018-2019,
26% of Aboriginal and Torres Strait Islander people had never consumed alcohol or were
abstinent from alcohol in the past year in comparison to 21% of the general Australian
population (AIHW, 2020). A further encouraging trend is the reduction in alcohol related
deaths in Aboriginal and Torres Strait Islander people by 40% over 20 years, with 31 deaths
per 100,000 in 1998 compared with 18 deaths per 100,000 in 2018 (Figure 1). Single
occasion risky alcohol intake is also declining in Aboriginal and Torres Strait Islander people,
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with 54% drinking more than four standard alcoholic drinks during one sitting in the past
twelve months in 2018-2019 compared to 57% in 2012-2013.
Aboriginal and Torres Strait Islander people are acutely aware of the harmful effects
of alcohol on their health and that of the broader community and in many instances have
implemented their own interventions to address the problem over the years (Wilson et al.,
2010). It is important to note that most Aboriginal and Torres Strait Islander people either
abstain from alcohol or do not drink alcohol at levels harmful to their overall health (Gray et
al., 2018). However, ongoing efforts and resources are needed to reduce alcohol related
morbidity and mortality in Aboriginal and Torres Strait Islander people. Solutions will also
involve public health measures that understand and address the underlying complex social
inequalities that contribute to the vicious cycle of ongoing misuse.

Figure 1
Age Standardised Mortality Rate Related to Alcohol Use from 1998 to 2018 in NSW, Qld,
WA, NT and SA Among Aboriginal and Torres Strait Islander People and Non-Indigenous
People.

Note. From Aboriginal and Torres Strait Islander Health Performance Framework 2020 summary report, by
AIHW. Copyright AIHW 2020.
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Metabolic Dysfunction-Associated Fatty Liver Disease
Non-alcoholic fatty liver disease is a leading cause of chronic liver disease worldwide
(Loomba & Sanyal, 2013). It is defined by an excessive amount of fat in the liver, steatosis,
unaccounted for by other factors such as alcohol use (Wong et al., 2018). More recently it
has been renamed metabolic dysfunction-associated fatty liver disease (MAFLD) to more
accurately represent the disease, its subphenotypes and its close association with obesity
and metabolic syndrome (Eslam et al., 2020). By 2030 it is estimated that the prevalence of
MAFLD in Australia will rise by 25% with over seven million cases projected (Adams et al.,
2020). Furthermore, incident MAFLD related mortality in Australia is estimated to increase by
85% between 2019 and 2030. The prevalence amongst Aboriginal and Torres Strait Islander
people is less well known. In a study of patients with chronic liver disease, 3% were noted to
have MAFLD or non-alcoholic steatohepatitis (NASH) (Valery et al., 2020). Another study of
HCC found that 6.1% had MAFLD/NASH (Wigg et al., 2021). However, this is likely an
underrepresentation given the recognised poor coding for this condition. The prevalence of
MAFLD is often underestimated in healthcare databases that use International Classification
of Diseases (ICD) codes, with a recent study finding the prevalence of MAFLD
underestimated by 42.9% (Hayward et al., 2021). Diabetes, a surrogate for MAFLD, is also
significantly more prevalent in Aboriginal and Torres Strait Islander people with rates ranging
between 3.5% and 33.1% (Nguyen et al., 2016). Obesity (BMI ≥30 kg/m), another risk factor
for MALFD, is also more prevalent among Aboriginal and Torres Strait Islander people
(Thurber et al., 2018). A study in New South Wales, Australia found that 39% of Aboriginal
and Torres Strait Islander people were obese compared to 22% of non-Indigenous
participants (Thurber et al., 2018). This worrying trend indicates we will see more cases of
MAFLD amongst Aboriginal and Torres Strait Islander people in the future, adding to the
overall burden of liver disease.
Currently, despite intensive research in the area, the only available treatment for
MAFLD is weight loss. A 10% reduction in weight has been shown to improve liver fat and
fibrosis and is the recommended weight loss goal for patients (Vilar-Gomez et al., 2015).
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MAFLD is important to recognise as it can be one of the first manifestations of metabolic
syndrome. Addressing MAFLD/obesity with weight loss can prevent future metabolic
complications including hypertension, dyslipidaemia and diabetes and subsequent
cardiovascular morbidity (Abdelaal et al., 2017).
Cirrhosis
All chronic liver diseases predispose individuals to the development of advanced
fibrosis/cirrhosis (Powell et al., 2019). Cirrhosis is often asymptomatic but with ongoing
injury, decompensation may occur. Decompensation is heralded by the complications of
cirrhosis which include the development of ascites, variceal bleeding and hepatic
encephalopathy, jaundice, renal dysfunction and HCC. Decompensation is an important
clinical event as it indicates a significantly reduced survival. Decompensation is associated
with an average two-year survival ranging from 38% to 70%, depending on severity
(D’Amico et al., 2006).
Unfortunately, Australian data suggests that hospitalisations related to cirrhosis and
decompensation are increasing. A study in Queensland, Australia found that hospital
admissions due to cirrhosis increased 1.6-fold over the past eight years (Powell et al., 2019).
Aboriginal and Torres Strait Islander people were overrepresented among admitted patients
with the number increasing by 8.8% from 201 admissions in 2008 to 341 in 2016. Another
study in Queensland found that 7% of patients admitted with chronic liver disease (CLD)
between 2008 to 2017 identified as an Aboriginal and/or Torres Strait Islander person
(Valery et al., 2020). Compared to non-Indigenous patients, more Aboriginal and Torres
Strait Islander patients were younger than 50 years of age (44% versus 19% of nonIndigenous patients), had CLD due to alcohol related liver disease (70% versus 47%),
resided in the most disadvantaged areas (51% versus 26%), presented via the Emergency
Department (68% versus 47%), had a higher rate of readmission and a lower overall
survival.
Management of cirrhosis and decompensated cirrhosis is complex and challenging
and requires high quality coordinated care approaches that integrate the patient with both
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primary and tertiary care. Coordinated care models based on chronic disease management
principles have been described and have shown promise in a small randomised controlled
pilot trial (Wigg et al., 2013). Such models aim to create improved relationships between
patients and the healthcare system using nurse coordinators and better implement the many
evidenced based treatments for cirrhosis and decompensation. Treatment of primary liver
disease (antiviral therapy, weight loss, alcohol abstinence), management of complications
(diuretics and large volume paracentesis for ascites, lactulose and rifaximin for hepatic
encephalopathy, beta blocker and endoscopic therapy to prevent variceal haemorrhage,
dietetic input for malnutrition), regular monitoring, improved education and self-management
are all goals of this model. Designing chronic disease models for cirrhosis that are relevant
and appropriate for Aboriginal and Torres Strait Islander people is an important clinical
priority, given the overrepresentation of this group in cirrhosis-related admissions.
Hepatocellular Carcinoma (HCC)
Aboriginal and Torres Strait Islander people with cirrhosis (and with non-cirrhotic
HBV over 50 years of age) are at an increased risk of developing HCC, the most common
primary liver cancer (Villanueva, 2019). Between 2009 and 2013 the incidence rates for HCC
in Aboriginal and Torres Strait Islander people was 2.4-fold higher compared to nonIndigenous people (AIHW, 2018). Indeed, HCC is one of the most common causes of
cancer-related mortality in Aboriginal and Torres Strait Islander people. The age
standardised mortality rate from HCC was also 2.4-fold higher in Aboriginal and Torres Strait
Islander people compared to non-Indigenous people. This difference in HCC survival
between Aboriginal and Torres Strait Islander and non-Indigenous people is higher than for
any other cancer.
Epidemiologically, HCC has many significant differences in Aboriginal and Torres
Strait Islander people compared with HCC in non-Indigenous people. Differences in
Aboriginal and Torres Strait Islander HCC patients include a higher comorbidity burden,
younger age at diagnosis (60 versus 65 years), lower socioeconomic status, higher rurality
(52% versus 3% remote/very remotely living) and a greater proportion affected are female
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(31% versus 18%) (Wigg et al., 2021). Aboriginal and Torres Strait Islander HCC patients
also tend to have multiple HCC cofactors (i.e., viral hepatitis, alcohol misuse, diabetes and
obesity) with 51% of cases having two or more cofactors, the most common being viral
hepatitis and alcohol. Aboriginal and Torres Strait Islander patients also tend to receive
curative treatment less often than non-Indigenous patients (6.6% versus 14.5%, p=0.001)
which contributes to the higher mortality rate seen in Aboriginal and Torres Strait Islander
people as well as the lower five-year survival (10.0% versus 17.3%, p=0.001).
As per other liver diseases, the higher prevalence and poorer outcomes of HCC for
Aboriginal and Torres Strait Islander people suggest the urgent need to understand and
address the factors contributing to these differences including improved detection of cirrhosis
and increased uptake of liver ultrasound surveillance in those at risk (Villanueva, 2019; Wigg
et al., 2021). Detection of HCC at early stages is critical as early-stage HCC has curative
treatment options including liver resection, liver transplantation, percutaneous ablation and
radiotherapy. Intermediate stage HCC also has treatment options including trans arterial
chemotherapy and systemic therapy, that although not curative, have been shown to
improve survival in randomised controlled trials (Finn et al., 2020; Llovet et al., 2002; Lo et
al., 2002).
Liver Transplantation
Liver transplantation is one of the treatment options in decompensated cirrhosis and
early-stage HCC. Despite Aboriginal and Torres Strait Islander people being
disproportionately affected by liver disease, less Aboriginal and Torres Strait Islander
patients proceed to liver transplantation and are underrepresented in the Australian liver
transplant population overall (Chinnaratha et al., 2014). Between 1985 and 2012, out of
3493 liver transplants only 45 (1.3%) were Aboriginal and Torres Strait Islander people. The
reasons for this are unknown, however may relate to less early detection and referral of liver
disease in primary care, cultural barriers leading to lack of referral, or higher rates of
contraindication/comorbidities of referred patients.
Although transplanted less frequently, encouragingly the median overall survival was
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similar between Aboriginal and Torres Strait Islander and non-Indigenous people. However,
in paediatric transplant recipients there was a trend towards increased re-transplantation and
mortality rates for those living in remote areas. Previous studies have also shown that rural
areas are also associated with less liver transplant waitlist registration and transplantation
(Axelrod et al., 2008; Chinnaratha et al., 2014). This trend is concerning given that 16% and
45% of Australians living in remote and very remote areas, respectively, are Aboriginal and
Torres Strait Islander people (ABS, 2018).
Clearly, there is a need to understand and address the barriers to liver
transplantation for Aboriginal and Torres Strait Islander people. A starting point may be
learning from the experience of kidney disease and transplantation in Australia. A
comprehensive review into the hurdles, practical challenges and service gaps faced by
Aboriginal and Torres Strait Islander patients receiving treatment for kidney disease has
already been performed (Garrard & McDonald, 2019). From this review, funding was
established for the National Indigenous Kidney Transplantation Taskforce, involving
Aboriginal and Torres Strait Islander representatives, responsible for implementing and
evaluating the priority recommendations of the review. A similar approach seems now
warranted for liver disease and liver transplantation.
Towards Improving Outcomes for Aboriginal and Torres Strait Islander Liver Diseases
Liver disease affects Aboriginal and Torres Strait Islander people disproportionally.
Although effective and evidence-based treatments are available for all major liver diseases
(hepatitis B vaccination, antiviral therapy, alcohol abstinence, weight loss, liver
transplantation), improving outcomes remains a significant challenge. Potential approaches
to address these challenges are outlined below.
Understanding social determinants of health
Liver diseases in Aboriginal and Torres Strait Islander people are intimately linked to
social determinants of health. Poverty, poor health literacy, rurality and poor access to care
are all facilitators of the key drivers for liver disease in Aboriginal and Torres Strait Islander
people including viral hepatitis, alcohol misuse and obesity/metabolic syndrome. Without

https://ro.ecu.edu.au/aihjournal/vol3/iss4/5
DOI: 10.14221/aihjournal.v3n4.5

12

Tashkent et al.: Liver Disease in Aboriginal and Torres Strait Islander People

political will and effective public health interventions to address these inequalities, the
prospects for health care interventions alone to achieve major improvements remain
guarded.
Co-design and Strengths-Based Approach
Effective health interventions for liver diseases will need to involve close
collaboration with Aboriginal and Torres Strait Islander communities to co-design culturally
appropriate programs that draw on the traditional strengths and beliefs of these communities
and combine them with western models of care (Dillon, 2021). Such an approach is
particularly relevant in remote communities where language barriers and traditional health
beliefs must be considered before planning new health interventions.
Improving Health Literacy Surrounding Liver Disease
A significant challenge for improving liver disease outcomes is improving health
literacy for both patients and health care workers in primary care (Dunn & Conrad, 2018;
Kaps et al., 2018; Poureslami et al, 2016). Liver disease is largely an unrecognised epidemic
with opportunities for early detection and treatment often missed. Avoiding a sole focus on
hepatitis B, understanding the emerging importance of MAFLD and the additive effects of
multiple liver cofactors are needed. The often asymptomatic nature of liver disease, the need
for early detection and knowledge of the highly effective therapies now available are
concepts that need greater focus in primary health care education.
Improving Detection and Screening of Liver Disease in Primary Care
The long asymptomatic phase of many liver diseases, the high prevalence of liver
disease and the availability of highly effective therapies make screening for liver disease a
critical part of primary care for Aboriginal and Torres Strait Islander people. Our
recommendations for screening are summarised in Table 1.
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Table 1
Recommended Screening Tests for Hepatitis B, Hepatitis C, Advanced Fibrosis/Cirrhosis
and Hepatocellular Carcinoma.

Screening
test(s)

Hepatitis B
(HBV)
Hepatitis B
surface antibody
(HBsAb),
Hepatitis B
surface antigen
(HbsAg),
and Hepatitis B
core total
antibody (HbcAb)
(Hepatitis B Virus
Testing Policy
Expert Reference
Committee, 2020)

Hepatitis C
(HCV)
Hepatitis C
serology
(HCV
antibodies)

Advanced fibrosis/
cirrhosis
Fibrosis-4 (Fib 4) score
(using platelet count, ALT
and AST combined with
age)

Hepatocellular
carcinoma
Six-monthly
abdominal
ultrasound
and

(Sterling et al., 2006).
(Hepatitis C
Virus
Infection
Consensus
Statement
Working
Group, 2020)

Or
APRI score
(AST to platelet ratio
index)
(Wai et al., 2003)

α‐fetoprotein
(AFP)
(Lubel et al.,
2020).

and
Vibration controlled
elastography
(Fibroscan®)
or
Shear wave elastography
(Mueller & Sandrin,
2010)

Given the high prevalence of HCV and HBV in Aboriginal and Torres Strait Islander
people we recommend screening for these infections in all adults as per Table 1. We also
recommend screening for liver disease in all Aboriginal and Torres Strait Islander patients
with the following risk factors; alcohol misuse history, obesity/diabetes, family history of HCC
and abnormal liver function tests. Baseline testing should include liver function tests,
complete blood count, INR and abdominal ultrasound. Liver ultrasound is useful to detect
advanced cirrhosis (nodular liver edge, ascites) but lacks sensitivity for the detection of early
cirrhosis/advanced fibrosis.
A key aspect of liver disease screening involves assessment of fibrosis, as progressive
fibrosis is the key determinant of prognosis for all liver diseases. A number of simple fibrosis
assessment tools are now readily available and accessible in primary care. All these fibrosis
tests are non-invasive and liver biopsy is now rarely required to achieve a diagnosis of
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advanced fibrosis/cirrhosis. All have strengths and limitations in fibrosis assessment and
must be interpreted in the correct clinical context. Key fibrosis assessment tools include:
Fibrosis-4 (Fib 4)
Initially developed to non-invasively assess fibrosis in those with Hepatitis C and HIV
co-infection and to avoid recurrent liver biopsy. The score uses platelet count, ALT and AST
combined with age to calculate a score that correlates with the level of fibrosis (Sterling et
al., 2006). Calculators are available online (University of Washington, 2022). A score less
than 1.45 has a negative predicable value of 90% for advanced fibrosis whereas a score
greater than 3.25 has a 97% specificity and positive predicate value of 65% for advanced
fibrosis (Sterling et al., 2006). Fib4 score is a simple way to rule out cirrhosis/fibrosis.
APRI Score (AST to platelet ratio index)
The APRI Score is another score that can be used to predict fibrosis. Calculators can
be found online (University of Washington, 2022) and require only AST and platelet count.
The aim of developing this score was to find a cheap, non-invasive way to estimate fibrosis.
A score less than 0.5 has a high negative predictive value (Wai et al., 2003). Similarly, to
Fib4 score, the APRI score’s strength is ruling out cirrhosis, but it is less reliable at picking
up cirrhosis (Yilmaz et al., 2011).
Vibration Controlled Elastography (Fibroscan®)
Vibration Controlled Elastography (VCE) is a non-invasive imaging modality that can
be used to assess the stiffness/hardness of the liver. It uses low frequency vibration waves
and measures the amount of time that the wave takes to travel from skin to the liver. It does
not cause any pain to the patient. As depicted below in Figure 2, a transducer probe is
placed between the ribs aimed at the right lobe of the liver. The probe sends a low amplitude
wave to the liver, this produces a wave through the liver tissue which can be measured.
Normal liver stiffness is in the range of 4-6 Kilopascals (kPa) and cirrhosis is found at
>12.5kPa (Mueller & Sandrin, 2010). The main strength of VCE in ruling out advanced
fibrosis rather than detecting it, relates to its high negative predictive value. A limitation of
this technology is accessibility, with most units located at tertiary care liver centres only.
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Figure 2
Vibration Controlled Elastography

Note. VCE probe on patient. The probe is placed between the ribs and a minimum of 10 elastography
measurements are taken.

Figure 3
Vibration Controlled Elastography Result

Note. VCE results demonstrating a median liver stiffness of 4.6 kPa, with low variability of measurements
(IQR/median ratio = 24%) highly suggestive of absent or minimal fibrosis.

Shear wave elastography
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This is a related ultrasound technology with similar performance characteristics to
VCE but is now widely accessible to general practitioners as an “add on” to standard liver
ultrasonography offered by many radiology companies.
Improving surveillance for HCC
Once advanced fibrosis/cirrhosis has been identified, affected patients should be
enrolled in a six-monthly liver ultrasound surveillance program together with monitoring
serum α‐fetoprotein to detect early curable HCC and reduce HCC-related mortality (Lubel et
al., 2020). Whilst serum α‐fetoprotein can be associated with false‐positive results, overall,
when paired with ultrasound it improves earlier detection of HCC compared to ultrasound
alone (Lubel et al., 2020). Other complications also need to be screened for including bone
disease, malnutrition, and vaccination for hepatitis A and HBV, if non-immune. The reality is
that HCC surveillance and cirrhosis care is challenging, and adherence is often poor,
particularly in remote communities with suboptimal access to radiology facilities and
specialist care (Parker et al., 2014). Robust models of care and protocols are required to
achieve acceptable adherence in all practice settings.
Mobile liver clinic models
Mobile liver clinics to Aboriginal and Torres Strait Islander communities in remote
areas have emerged in several Australian jurisdictions and aim to increase uptake of
screening and surveillance tests and treatment in remote settings. The concept has been
energised by recent advances in technology including the development of high quality
mobile elastography and ultrasound devices (Figure 4). The ongoing development of point of
care pathology testing for HCV and HBV also makes delivering high quality care in remote
settings more feasible. These clinics have linkages with liver disease clinicians and use an
on-site sonographer with portable elastography (FibroScan®), ultrasound scans and
educational apps in the patient’s Aboriginal and/or Torres Strait Islander language (Davies et
al., 2015). Significant community engagement by local health care workers, prior to visits, is
needed to ensure adequate attendance during mobile liver clinic visits. Such mobile clinics
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have reported improved HCC surveillance and monitoring and treatment uptake of hepatitis
B (Hla et al., 2020). However, further evaluation of these clinics in terms of efficacy and cost
effectiveness is required before translation into widespread application/national programs
can be advocated.
Figure 4
A Mobile Liver Clinic in Remote South Australia Utilising Fibroscan and Ultrasound.

Conclusions
Aboriginal and Torres Strait Islander people are disproportionally affected by liver
disease resulting in significant morbidity and mortality. However, all major causes of liver
disease can be prevented and significant recent advances in medical technology and
treatment mean that most liver disease can now be easily detected and effectively treated.
The current challenge is to raise awareness of this growing epidemic in Aboriginal and
Torres Strait Islander people and to harness the strengths of Aboriginal and Torres Strait
Islander people and healthcare services to improve outcomes.
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